A Phase I Study of Ruxolitinib and Duvelisib to Treat Recurrent or Persistent T-Cell or NK-Cell Lymphomas

Share
Print

Full Title

Phase I Multicenter Study of Ruxolitinib and Duvelisib in Relapsed or Refractory T- or NK-Cell Lymphomas

Purpose

The purpose of this study is to find the highest doses of ruxolitinib and duvelisib when given together in patients with T-cell or NK-cell lymphoma that has come back or continued to grow despite prior treatment. The Food and Drug Administration (FDA) has approved ruxolitinib as a treatment for myelofibrosis and polycythemia vera (other blood disorders). The FDA has approved duvelisib to treat follicular lymphoma, small lymphocytic lymphoma, and chronic lymphocytic leukemia. The use of these two drugs together in this study is considered investigational.

Both duvelisib and ruxolitinib block proteins that have been shown to be active in many types of lymphoma. Blocking these proteins can cause cancer cells to die, which could slow or stop the growth of tumors. Both drugs are taken orally (by mouth).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have T-cell or NK-cell lymphoma that has come back or continued to grow despite prior treatment.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Alison Moskowitz at 646-608-3726.

Protocol

21-176

Phase

I

Investigator

Co-Investigators